Bei Akademie registrieren
Rocket One stock, Hoth Therapeutics

Rocket One stock: Hoth ends HT-001 trial early, eyes Phase 3

Published on 11/13/2026 at 00:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rocket One stock is in focus after subsidiary Hoth Therapeutics ended its HT-001 Phase 2a trial early. FDA discussions are next.

FDA feedback is the next catalyst

  • Hoth Therapeutics ended the HT-001 Phase 2a trial early after reviewing interim efficacy and safety data.
  • The company plans to complete its data review and seek FDA input on a potential pivotal study.
  • HT-001 remains investigational and has not been approved by the FDA for any indication.
Rocket One stock, Hoth Therapeutics, HT-001, clinical trial, FDA, biotechnology, Illustration mit AI erstellt.
Rocket One stock, Hoth Therapeutics, HT-001, clinical trial, FDA, biotechnology, Illustration mit AI erstellt.

Rocket One said on Tuesday, November 3, 2026, that its biotechnology subsidiary Hoth Therapeutics had ended the Phase 2a clinical trial of HT-001 early after reviewing positive interim efficacy findings. The announcement, carried by PR Newswire, links the decision to interim efficacy and safety data.

Potential move toward Phase 3

Hoth plans to complete the remaining data review and analysis needed for its regulatory submission and development strategy. It intends to ask the U.S. Food and Drug Administration for feedback on a possible pivotal study, including its design, efficacy endpoints, patient population, statistical approach, safety requirements and manufacturing readiness.

The next development step therefore depends on regulatory feedback and the completion of additional activities. The company did not present the interim findings as final: it said the results are preliminary and may change as more data are collected and finalized.

Investigational oncology support

HT-001 is a topical formulation of aprepitant being developed for dermatologic toxicities associated with epidermal growth factor receptor inhibitor cancer therapies. The treatment is designed to deliver the active ingredient directly to affected skin, with the program evaluating efficacy, safety and tolerability. HT-001 has not been approved by the FDA for any indication.

Rocket One's business profile

Rocket One describes itself as a technology company with activities spanning artificial intelligence infrastructure, advanced semiconductor technologies, space and defense systems, and autonomous platforms. Hoth Therapeutics is its biotechnology subsidiary, focused on investigational treatments for unmet patient needs, while Tracer Drone Technologies provides drone hardware, software, training and technical support. The combination gives Rocket One exposure to technology, autonomous systems and early-stage life-science development.

Rocket One at a glance

  • Company: Rocket One Inc.
  • Ticker: RKTO
  • Business areas: AI infrastructure, semiconductors, space and defense systems, autonomous platforms and biotechnology
  • Clinical program: HT-001 for dermatologic toxicities linked to EGFR inhibitor cancer therapies

US equities provide the broader market backdrop for Rocket One stock.

Disclaimer...
en | boerse | 70501302 |